At the Cleveland Clinic Taussig Cancer Institute, patients from around the world, and around the USA, come to us for management of breast cancer.
We have a multi-disciplinary clinic involving surgeons, radiation oncologists, medical oncologists, and pathologists, who work closely with our scientists to develop novel approaches to the diagnosis and management of breast cancer. Currently, we have a broad menu of options available.
At the larger level, we collaborate actively with many of the multi-centered trial groups, doing randomized clinical trails, looking at novel therapies versus the best-established therapies, in most cases using molecular biology to refine the choice of treatment.
In house, we have a number of programs that involve what we call phase 1 and phase 2 trials. And this involves the use of novel approaches where we're still refining them, trying to work out the optimal dose, optimal strategy, and then, novel therapies where we're trying to identify how active they really are.
We're looking at circulating tumor cells and looking at the molecular types of breast cancer cells in the blood stream to aid us in the prediction of outcome of breast cancer.
We use novel anti-cancer drugs; and in a very exciting program, we're about to launch a study of a phenomenon called "chemobrain." That's where women who are getting chemotherapy for breast cancer find it a little difficult to think clearly and do their tasks.
And we're studying that in depth using a bunch of electrical and electrophysiological probes.
We anticipate improving treatment as we move forward in this carefully structured program involving science and medicine.